Genetic Engineering & Biotechnology News
Tutorials: December 01, 2017 (Vol. 37, No. 21)
MALDI-MS Detection Schemes Hasten Drug Development
Novel Method to Finding New Drug Candidates with Promising Therapeutic Applications
Rohan Thakur, Ph.D.
Over the last few decades, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has proven its usefulness and robustness in many applications. Recent innovations in MALDI-MS utilize advances in two detection schemes being applied to accelerate preclinical drug discovery: one in ultra-high-throughput screening (uHTS) programs, the other in drug-distribution MALDI imaging studies.
The recurring principle—fail early, fail cheap—drives innovation in pharma who seek to rapidly generate more compound leads or “hits” as well as involve ADME/TOX (absorption, distribution, metabolism, excretion/toxicity) earlier in the discovery process to quickly eliminate candidates. New initiatives have undoubtedly driven the growth (2015–2016) in drug pipelines to an estimated 11.5 %.1
原文鏈接：
https://www.genengnews.com/gen-articles/maldi-ms-detection-schemes-hasten-drug-development/6212?q=MALDI-MS Detection Schemes Hasten Drug Development
